Three biotechs raise $700M in rare burst of IPO activity [Yahoo! Finance]
Kyverna Therapeutics, Inc. (KYTX)
Company Research
Source: Yahoo! Finance
offerings Thursday, a flurry of activity after a largely fallow summer in which few biotechnology companies made the jump to public markets. Cancer biotech Bicara Therapeutics secured $315 million in the third-largest IPO of the year, according to BioPharma Dive data . Autoimmune drug developer Zenas BioPharma followed with a $225 million stock sale , while MBX Biosciences, which is studying endocrine and metabolic conditions including obesity, raised $163 million All three met projections they set the past few weeks. Bicara hiked its offering size by 25% before pricing and still sold more shares than anticipated. Zenas and MBX upsized their IPOs as well. The trio of offerings is a notable occurrence this year. So far, 18 biotechs have now priced IPOs in 2024, in line with each of the prior two years but well below pre-pandemic totals. More than half currently trade below their offering price, BioPharma Dive data show. As in the past two years, lengthy dry spells have followed
Show less
Read more
Impact Snapshot
Event Time:
KYTX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
KYTX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
KYTX alerts
High impacting Kyverna Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
KYTX
News
- What Makes Kyverna Therapeutics, Inc. (KYTX) a New Buy Stock [Yahoo! Finance]Yahoo! Finance
- Investors in Kyverna Therapeutics, Inc. Should Contact Levi & Korsinsky Before February 7, 2025 to Discuss Your Rights – KYTXGlobeNewswire
- KYTX Deadline: KYTX Investors Have Opportunity to Lead Kyverna Therapeutics, Inc. Securities LawsuitPR Newswire
- SHAREHOLDER ACTION REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Kyverna TherapeuticsPR Newswire
- Kyverna Therapeutics, Inc. Class Action: Levi & Korsinsky Reminds Kyverna Therapeutics, Inc. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of February 7, 2025 - KYTXPR Newswire
KYTX
Earnings
- 11/13/24 - Miss
KYTX
Sec Filings
- 1/24/25 - Form 4
- 1/24/25 - Form 3
- 1/21/25 - Form 8-K
- KYTX's page on the SEC website